Last updated on June 2019

Setmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity

Brief description of study

The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight and other factors in patients with pro-opiomelanocortin (POMC) deficiency obesity due to rare bi-allelic loss-of function POMC or PCSK1 genetic mutations.

Clinical Study Identifier: NCT02896192

Find a site near you

Start Over